1Morris JC, Selkoe DJ. Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview [J]. Neurobiol Aging. 2011,32 Suppl 1: S1-3. 被引量：1
2Reiman EM, McKhann GM, Albert MS, et al. Clinical impact of updated diagnostic and research criteria for Alzheimer's disease [J]. J ClinPsychiatry. 2011,72 (12): e37. 被引量：1
3Mattsson N, Ros6n E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers [J]. Neur- ology. 2012,78 (7): 468-476. 被引量：1
4Buclahave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of 13-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia [J]. Arch Gen Psychiatry. 2012,69 (1): 98-106. 被引量：1
5Westman E, Cavallm L, Muehlboeck JS, et,71. Sensitivity and specificity of medial temporal lobe visual ratings and multivar- iate regional MRI classification in Alzheimer's disease [J]. PLoS One. 2011,6 (7): e22506. 被引量：1
6Villemagne VL, Mulligan RS, Pejoska S, etM. Comparison of (11) C-PiB and (18) F-florbetaben for AI3 imaging in ageing and Alzheimer's disease [J]. Eur J Nucl Med Mol Imaging. 2012. [Epub ahead of print]. 被引量：1
7Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease [J]. Nat Genet. 2011,43 (5): 436-441. 被引量：1
8Deng YL, Liu LH, Wang Y, et al. The prevalence of CD33 and MS4A6A variant in Chinese Hart population with Alzhei- mer'sdisease [J]. HumGenet. 2012. [Epub ahead of print]. 被引量：1
9Chart M, Chart MW, Lob TW, et al. Evaluation of nanofluidics technology for high-throughput SNP genotyping in a? clinical setting[J].l'Mol Diagn. 2011,13 (3): 305-312. 被引量：1
10Hampel H, Biirger K, Teipel SJ, eta1. Core candidate neuro- chemical and imaging biomarkers of Alzheimer's disease [J]. Alzhemiers Dement. 2008,4 (1): 38-48. 被引量：1
